Viberzi litigation
Claims allege that the IBS drug Viberzi causes severe, sometimes fatal pancreatitis in patients without a gallbladder.
Free case review
What the claims allege
In 2017 the FDA warned that Viberzi should not be used in patients without a gallbladder after reports of serious pancreatitis, some within the first doses. Claims allege the contraindication came too late for patients already harmed.
Injuries named in the litigation
- Acute pancreatitis
- Sphincter of Oddi spasm
- Hospitalization and death reported in FDA communications
Who may qualify
If you took Viberzi after gallbladder removal and were hospitalized with pancreatitis, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.